Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$8.44 USD
-0.53 (-5.91%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $8.42 -0.02 (-0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NRIX 8.44 -0.53(-5.91%)
Will NRIX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRIX
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Other News for NRIX
Technical picture remains unchanged for NRIX after it falls 5.91% on September 20
NRIX forms Stochastic Buy Signal on September 18
Pocket Pivot appears for NRIX after 1.54% move
Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus
Nurix Therapeutics (NRIX) Gets a Buy from Barclays